NewsPronto

 
The Times


.

ACN Newswire

Read more press releases from ACN Newswire here

Nanobiotix Reports Positive Phase I/II Preliminary Data on Feasibility and Safety of NBTXR3 in Liver Cancers Trial

  • Written by ACN Newswire

image

image
- Good safety and feasibility of the treatment at 10% dose level- Third indication in global development confirming transferability across different cancers

Paris, France and Cambridge, Massachusetts, USA, Dec 15, 2016 - (ACN Newswire) - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel...

Read more: Nanobiotix Reports Positive Phase I/II Preliminary Data on Feasibility and Safety of NBTXR3 in...